Chordate Medical's CEO, Anders Weilandt, will present Ozilia at Swiss Nordic Bio in Zurich on March 7th. Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting Nordic and Swiss startups in the Life Science sector with investors and industry partners.
"As we continue to penetrate key markets, we will increasingly focus on raising awareness about the company and Ozilia within the industrial and investor circles surrounding Life Science. Swiss Nordic Bio is one of several important forums in this context during the spring where we participate to present Ozilia's potential", said Anders Weilandt, CEO of Chordate.
Swiss Nordic Bio has been held for 17 years and was previously known as the Swiss Scandinavian Bio-Business Seminar. The conference is hosted by Vator Securities and Business Sweden and organized together with stakeholders from the Nordic countries in collaboration with Swiss partners.
"The conference focuses on biotechnology, medtech, and the pharmaceutical industry. In addition to development companies like Chordate, and investors, global companies from these three fields also participate, making this the perfect forum for us to be a part of.”
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.